iBio regains Nasdaq minimum bid price compliance; deficiency notice closed

iBio, Inc.

Received notice on Nov 4, 2025 from Nasdaq confirming compliance with Listing Rule 5550(a)(2).
Original deficiency letter dated July 29, 2025 for bid price below $1.00 from June 13 to July 28, 2025.
Matter is now closed; no further action required by the company.
Regained compliance after common stock (IBIO) traded at or above $1.00 for required period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.